

ICMJE DISCLOSURE FORM

Date: August 3, 2022

Your Name: Rutika Mehta MD, MPH

Manuscript Title: Nivolumab plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastroesophageal junction cancer- regional differences in efficacy

Manuscript number (if known): APM-22-851

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<input checked="" type="checkbox"/> None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input checked="" type="checkbox"/> None	
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	Eli Lilly	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Natera, Daiichi Sankyo, Foundation Medicine	
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Eli Lilly, BMS, Astellas, Boston Gene	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Volunteer Advisory Board Member for Debbie's Dream Foundation	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

Please summarize the above conflict of interest in the following box:

Rutika Mehta has received consulting fees from Eli Lilly, has served on speaker bureau for Natera and Daiichi Sankyo, has accepted compensation for a talks from Foundation Medicine, has served on advisory board for Eli Lilly, BMS, Astellas and Boston Gene and is a volunteer advisory board member for Debbie's Dream Foundation.

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: August 3, 2022

Your Name: Manish A. Shah, MD

Manuscript Title: Nivolumab plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastroesophageal junction cancer- regional differences in efficacy

Manuscript number (if known): APM-22-851

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<input checked="" type="checkbox"/> None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Merck, Bristol Meyers Squibb, Oncolys Biopharma	All to the institution
3	Royalties or licenses	<input checked="" type="checkbox"/> None	

4	Consulting fees	<input checked="" type="checkbox"/> None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None	
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Zymeworks	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	ASCO Leadership Council DeGregorio Foundation for Upper GI Malignancies – Scientific Advisory Board	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

Please summarize the above conflict of interest in the following box:

Manish Shah has received grants or contracts from Merck, Bristol Meyers Squibb, and Oncolys Biopharma, all to the institution. He serves on the Data Safety Monitoring Board for Zymeworks, and has a Leadership role as a volunteer for the ASCO Leadership Council and the Degregorio Foundation for Upper GI Malignancies.

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.